China Medical System receives lupus trial approval as analysts set CMS stock target at HKD 17.83

Published on 10/07/2026 at 07:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Latest-quarter revenue reached CNY 4,500.73 million on August 17, 2026. The average target for CMS stock is HKD 17.83.

CMS, KYG211081248, Illustration mit AI erstellt.

China Medical System Holdings Limited (ISIN KYG211081248) received approval for a systemic lupus erythematosus clinical trial for its CMS-D001 drug on September 14, 2026. The average analyst target for CMS stock stands at HKD 17.83, according to Investing.com.

Lupus trial adds pipeline depth

The approval covers a highly selective TYK2 inhibitor, CMS-D001, for systemic lupus erythematosus, according to MarketScreener on September 14, 2026. The same report lists pharmaceuticals as the company's sector and identifies the Hong Kong listing under ticker 867.

The event extends a development pipeline that also includes products in cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetics. MarketScreener lists 6,415 employees and describes China Medical System as a producer, marketer and distributor of medicines in China and overseas markets.

Quarterly figures support the valuation debate

China Medical System reported CNY 4,500.73 million in revenue and CNY 986.10 million in net income for its latest reported quarter, with the release dated August 17, 2026, according to Investing.com. Revenue increased from CNY 4,210.08 million in the previous quarter, while net income rose from CNY 547.71 million.

The quarter therefore produced a CNY 290.65 million revenue increase and a CNY 438.39 million net income increase against the preceding quarter. Investing.com also reports 9 Buy ratings and 1 Hold rating, giving the stock a Strong Buy consensus and an average 12-month target of HKD 17.83.

Hong Kong valuation remains the market anchor

China Medical System stock was at HKD 10.64 on the Hong Kong Stock Exchange on October 7, 2026 at 1:10 p.m. HKT, down HKD 0.14 from the prior close of HKD 10.78. Its 52-week range was HKD 9.51 to HKD 15.52, and market capitalization was HKD 25.9 billion.

The target comparison is substantial: HKD 17.83 stands HKD 7.19 above the quoted HKD 10.64 price. For investors, the lupus program adds a dated development milestone, while the latest quarterly figures provide the operating base behind the valuation discussion.

The further course of trading is shown by the continuously updated real-time quote of CMS stock.